Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yaotongning is a Traditional Chinese Medicine (TCM) capsule developed and manufactured by Jingfukang Pharmaceutical Group. It is primarily indicated for the treatment of lumbar-related conditions, including lumbar disc herniation, lumbar osteoarthritis, sciatica, and rheumatoid arthritis. The formulation typically contains processed *Strychnos nux-vomica* (Ma Qian Zi) as a key active ingredient, along with other herbs like *Ephedra*, *Achyranthes bidentata*, and *Boswellia*. It is designed to dispel wind, remove dampness, activate blood circulation, and relieve pain. Clinical evaluations, including post-marketing studies registered in the Chinese Clinical Trial Registry (ChiCTR), have focused on its efficacy and safety in treating lumbar disc herniation and osteoarthritis compared to other TCM formulations like Bitongning or Yaobitong.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yaotongning.